This article reports on the combined use of alefacept and etanercept in 3 patients whose psoriasis failed to respond adequately to etanercept. All patients maintained improvement for at least 8 weeks after completing 12 weeks of alefacept. No adverse events or infections were reported, and CD4+ T-cell counts remained above normal limits.Le texte complet de cet article est disponible en PDF.
| Funding sources: Research support from Abbott Laboratories, Biogen Idec, Genentech, and Synta Pharmaceuticals.
Conflicts of interest: Dr Krell is a consultant and speakers’ bureau participant for Amgen, Biogen Idec, and Genentech.
Reprints not available from the author.